168 related articles for article (PubMed ID: 29905380)
1. The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS.
Oka S; Ono K; Nohgawa M
Am J Hematol; 2018 Sep; 93(9):E220-E222. PubMed ID: 29905380
[No Abstract] [Full Text] [Related]
2. Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases.
Yoshida Y; Oguma S; Ohno H; Nakabo Y; Katsurada T; Kawahara M; Kawabata H
Int J Hematol; 2014 Jun; 99(6):721-5. PubMed ID: 24687918
[TBL] [Abstract][Full Text] [Related]
3. Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.
Nolte F; Mossner M; Jann JC; Nowak D; Boch T; Müller NZ; Hofmann WK; Metzgeroth G
Eur J Haematol; 2017 Mar; 98(3):302-310. PubMed ID: 27862375
[TBL] [Abstract][Full Text] [Related]
4. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
5. [Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].
Mishima M; Makita M; Sando Y; Yamamoto Y; Shiote Y; Hara Y; Yamamoto K; Imajo K
Rinsho Ketsueki; 2015 Jan; 56(1):35-7. PubMed ID: 25745966
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
[TBL] [Abstract][Full Text] [Related]
7. Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.
Hashimoto M; Itonaga H; Nannya Y; Taniguchi H; Fukuda Y; Furumoto T; Fujioka M; Kasai S; Taguchi M; Taniguchi H; Sato S; Sawayama Y; Atogami S; Iwasaki K; Hata T; Soda H; Moriuchi Y; Nakata K; Ogawa S; Miyazaki Y
Intern Med; 2020 Apr; 59(8):1081-1086. PubMed ID: 31875636
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
10. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
[TBL] [Abstract][Full Text] [Related]
11. [Unidentified Inflammatory Disease Induced by Azacitidine Therapy for Myelodysplastic Syndrome].
Inagaki S; Tamai Y; Yoshizawa M; Sato S; Kanbe E; Tanaka E
Gan To Kagaku Ryoho; 2015 Nov; 42(11):1443-6. PubMed ID: 26602409
[TBL] [Abstract][Full Text] [Related]
12. Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy.
Takaoka K; Hangaishi A; Ito A; Morioka T; Kida M; Usuki K
Intern Med; 2014; 53(19):2241-3. PubMed ID: 25274238
[TBL] [Abstract][Full Text] [Related]
13. A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics.
Nishiwaki S; Ito M; Watarai R; Okuno S; Harada Y; Yamamoto S; Suzuki K; Kurahashi S; Iwasaki T; Sugiura I
Leuk Res; 2016 Feb; 41():21-6. PubMed ID: 26651421
[TBL] [Abstract][Full Text] [Related]
14. Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?
Steiner N; Schwärzler A; Göbel G; Löscher W; Wanschitz J; Gunsilius E
Oncotarget; 2017 Jan; 8(3):5081-5091. PubMed ID: 27974705
[TBL] [Abstract][Full Text] [Related]
15. [Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine].
Kudo D; Shimizu M; Kuroda A; Suyama T; Shinagawa A; Ito S
Rinsho Ketsueki; 2017; 58(6):607-612. PubMed ID: 28679990
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
Tomonaga M; Kamae I
Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
18. Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
Guo Y; Liu Z; Duan L; Shen H; Ding K; Fu R
Invest New Drugs; 2022 Aug; 40(4):738-746. PubMed ID: 35576022
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.
Kyle RA; Therneau TM; Rajkumar SV; Larson DR; Plevak MF; Melton LJ
Mayo Clin Proc; 2004 Jul; 79(7):859-66. PubMed ID: 15244381
[TBL] [Abstract][Full Text] [Related]
20. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.
Za T; De Stefano V; Rossi E; Petrucci MT; Andriani A; Annino L; Cimino G; Caravita T; Pisani F; Ciminello A; Torelli F; Villivà N; Bongarzoni V; Rago A; Betti S; Levi A; Felici S; Gentilini F; Calabrese E; Leone G;
Br J Haematol; 2013 Mar; 160(5):673-9. PubMed ID: 23240810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
